Study guide

2.6 Mendelian Inheritance Patterns

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

2.6 Mendelian Inheritance Patterns

Key Takeaways Explain This Topic AI

Autosomal dominant transmission shows vertical pedigree pattern with male-to-male transmission possible; each child of an affected heterozygote has a 50% chance of inheriting the pathogenic allele when segregation is Mendelian

Autosomal recessive pedigrees are often horizontal; carrier × carrier matings yield 25% affected, 50% carrier, and 25% non-carrier offspring on average

X-linked recessive disease typically spares transmitting fathers’ sons, affects hemizygous males, and can produce manifesting females when X-inactivation is skewed or the variant is severe

Apparent de novo dominant disease still warrants discussion of germline (gonadal) mosaicism because recurrence risk is low but not absolute zero

X-linked dominant patterns lack male-to-male transmission; male lethality or severe male phenotypes and female expressivity differences are classic counseling cues

Last updated: August 2026

2.6 Mendelian Inheritance Patterns

Quick Answer: Master four core Mendelian modes— autosomal dominant (AD) , autosomal recessive (AR) , X-linked recessive (XLR) , and X-linked dominant (XLD) —by transmission rules on a pedigree, not by disease name alone. Then layer the exceptions boards love: de novo variants, germline mosaicism , and skewed X-inactivation in females.

Domain 2B items ask you to read a pedigree, predict who is at risk next, and explain why a “classic” pattern broke. Risk arithmetic lives in Domain 2A; here the job is pattern recognition and mechanism .

Autosomal Dominant (AD)

In classic AD disease, one pathogenic allele on an autosome is sufficient for disease predisposition (subject to penetrance—covered in 2.8).

  • Rule Clinical / exam meaning
  • Vertical transmission Affected individuals in successive generations when penetrance is high
  • Male-to-male transmission Possible and excludes X-linked inheritance
  • Segregation Each child of an affected heterozygote has ~ 50% chance of inheriting the allele
  • Sex ratio Males and females affected roughly equally (unless sex-limited expression)

Unaffected non-carriers Do not transmit the familial allele (ignore mosaicism/non-paternity/new mutation for this idealization)

Counseling anchors: Distinguish “has the familial variant” from “will develop the phenotype” when penetrance is incomplete. For severe pediatric AD conditions with fitness cost (e.g., many lethal skeletal dysplasias, some early neurodevelopmental disorders), a substantial fraction of index cases are de novo .

De Novo AD and Germline Mosaicism

A de novo pathogenic variant is present in the child but absent from parental blood (leukocyte) DNA. Parents are usually quoted a low empiric recurrence risk, but germline mosaicism (variant present in a fraction of parental gametes) means recurrence is not absolute zero . Exam-ready phrasing: “Most likely de novo; residual recurrence risk is low but not zero because of possible germline mosaicism; prenatal/preimplantation options can still be discussed if the familial variant is known.”

Somatic mosaicism in the affected person can produce milder or segmental phenotypes and may reduce transmission probability depending on germline involvement—do not equate blood-negative parents with “impossible recurrence” or mosaic probands with “cannot transmit.”

Autosomal Recessive (AR)

AR disease typically requires biallelic pathogenic variants (homozygous or compound heterozygous).

  • Rule Clinical / exam meaning
  • Horizontal pedigree Multiple affected siblings; parents usually unaffected carriers
  • Consanguinity Increases chance both parents share an ancestral allele
  • Carrier × carrier On average 1/4 affected , 1/2 carriers , 1/4 non-carriers

Affected × non-carrier All offspring carriers; none affected (assuming true non-carrier and complete genotyping)

Pseudodominance Affected person partners with a carrier → vertical-looking pedigree that is still AR

CGC traps: (1) Calling an isolated case “not genetic” because parents are healthy—AR and de novo AD both produce isolated cases. (2) Assuming ethnicity-based carrier rates replace partner testing when a familial variant is known—offer cascade testing for the known variant(s). (3) Confusing carrier probability after a negative screen (residual risk) with Mendelian segregation once genotypes are known.

X-Linked Recessive (XLR)

Pathogenic variants on the X chromosome; hemizygous males express disease; heterozygous females are usually unaffected or milder, with important exceptions.

  • Transmission clue Interpretation
  • No male-to-male transmission Fathers transmit their Y—not their X—to sons

Affected male → daughters All daughters inherit his X → all are obligate carriers (or affected if the condition is XLD / highly expressing)

  • Affected male → sons Sons get his Y → not at risk for that paternal X variant
  • Carrier female → sons Each son has 50% chance of being affected
  • Carrier female → daughters Each daughter has 50% chance of being a carrier

Manifesting female Possible with skewed X-inactivation , chromosomal anomalies (e.g., X;autosome translocation), compound heterozygosity/homozygosity, or mild alleles

Skewed X-inactivation: Random X-inactivation (lyonization) normally mosaics female tissues. Non-random skewing can silence the normal allele in enough cells that a heterozygous female shows disease features (classic teaching examples include some dystrophinopathy carriers or other XLR disorders). Boards test the concept : female phenotype does not automatically prove autosomal inheritance.

X-Linked Dominant (XLD)

One pathogenic X allele can produce phenotype in females; males may be more severely affected or nonviable for some loci.

  • Feature Exam use
  • No male-to-male transmission Same X biology as XLR
  • Affected females common Pedigrees may show more affected females if male lethality occurs
  • Male severity Hemizygous males often more severe; embryonic male lethality yields pedigree gaps

Examples (pattern recognition) Conditions such as Rett syndrome ( MECP2 ) are often framed as X-linked with frequent de novo occurrence in females; incontinentia pigmenti illustrates male lethality patterns

Do not memorize every XLD disease list; memorize how the pedigree behaves and when to suspect male lethality versus ascertainment bias.

Pattern Discrimination Table

  • Pattern Male-to-male? Typical parents of isolated case Key exception to teach
  • AD Yes possible Often one affected parent; or de novo Germline mosaicism; incomplete penetrance

AR Yes possible among affected relatives’ lines, but parents usually unaffected Both carriers Consanguinity; pseudodominance

  • XLR No Mother often carrier; may be de novo in male Manifesting females / skewing
  • XLD No Mother affected or de novo Male lethality; variable female severity
  • Putting Mendelian Rules into a Session

Draw or interpret the pedigree symbols and transmission arrows before naming a syndrome.

Ask whether male-to-male transmission is present or possible—this single check separates autosomal from X-linked hypotheses.

For severe AD presentations in a child with negative parental studies, counsel de novo + residual germline mosaicism honestly.

For X-linked families, explicitly map risk to daughters of affected males versus sons of carrier females .

Reserve quantitative Bayesian updates and population carrier frequencies for Domain 2A calculations—here, nail the mode .

Fluent Mendelian pattern language is what lets you later attach mitochondrial, imprinting, and multifactorial exceptions without collapsing everything into “50% or 25%.”